Breaking News, Collaborations & Alliances

Eisai Acquires License from Huya Bio

Will develop and market HDAC inhibitor in Japan and other Asian countries

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Eisai has entered into an exclusive license agreement with HUYA Bioscience International to develop and market the oral histone deacetylase (HDAC) inhibitor HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore. HBI-8000 is an oral HDAC inhibitor approved in China for use in the treatment of peripheral T-cell lymphoma (PTCL). Non-clinical data suggest HBI-8000 has epigenetic properties that work to regulate tumor cell growth, and the agent is believ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters